Clinical Trial Update: EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial [Phase 1, Phase 2]

View source ↗

Summary

A multicenter, randomized Phase 1/2 trial evaluating EDN in combination with TACE/HAIC and a second-line immune-targeted therapy versus TACE/HAIC alone for loca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• EDN

Snippet

Sponsor: Zhongda Hospital | Conditions: HCC - Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING